$NVLX Nuvilex's Provides Progress Update on Cell

$NVLX Nuvilex's Provides Progress Update on Cell Cloning Being Performed by Inno Biologics

2013-12-19 09:30 ET - News Release

SILVER SPRING, Md., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, provided an update today on the progress made by its contractor, Inno Biologics, regarding the cloning of the cancer-prodrug ifosfamide-activating cells that form the basis for the cancer treatment and will be encapsulated as part of the development of the treatment for Nuvilex's future clinical trials in advanced pancreatic cancer.

The cells being cloned at Inno Biologics are those that are able to convert ifosfamide, an anti-cancer prodrug, into its cancer-killing form. Ultimately, the cells obtained will be encapsulated using the Cell-in-a-Box ™ cellulose-based live cell encapsulation technology. Together with ifosfamide, the encapsulated cells form Nuvilex's treatment for advanced pancreatic cancer that will be used in the Company's future clinical trials.

To date, the cloning process at Inno Biologics has been going well with initial clones that have been isolated using the "State-of-the-Art" Clone-Pix ™ technology that allows for optimization of the clone isolation process. The To date, the cloning process at Inno Biologics has been going well with initial clones that have been isolated using the "State-of-the-Art" Clone-Pix ™ technology that allows for optimization of the clone isolation process.

In addition, a strategic planning meeting was held the week of November 24, 2013 to assess issues regarding the ongoing cloning activities. Participants included Dr. Robert F. Ryan, Nuvilex's Chief Scientific Officer, Datuk Dr. Ahmed Tasir Bin Lope Pihie, CEO of Inno Biologics, Dr. Walter H. Gunzburg, Chairman and Chief Technical Officer of Austrianova and Dr. Brian Salmons, CEO and President of Austrianova from whose company the rights to use the Cell-in-a-Box™ technology for the development of cancer treatments were acquired.

In commenting on the cloning process, Dr. Ryan stated, "We are confident with the results of the initial cloning process to this point which showed its capabilities to isolate multiple clones that were grown from single cells. This is critical as we move this project forward to insure the reproducibility of the future cancer treatments being advanced here at Nuvilex. We continue to make progress toward our goal of bringing this treatment option to clinical trials for advanced inoperable pancreatic cancer."

http://www.stockwatch.com/News/Item.aspx?bid=...p;region=U